IBCG (@ibcg_bladderca) 's Twitter Profile
IBCG

@ibcg_bladderca

We (the IBCG, International Bladder Cancer Group) are a group who are devoted to positively affecting the care of bladder cancer patients globally.

ID: 4859007953

linkhttp://ibcg.info calendar_today29-01-2016 04:40:35

1,1K Tweet

1,1K Followers

393 Following

Ashish M. Kamat, MD, MBBS (@urodocash) 's Twitter Profile Photo

Exciting opportunity for young investigators in #bladdercancer research! BCAN’s Career Development Award is now accepting submissions. This 3-year, $250K grant is your chance to drive innovation and make a lasting impact Bladder Cancer Advocacy Network IBCG

Roberto Contieri (@robertocontieri) 's Twitter Profile Photo

Honored to have contributed to the IBCG effort in providing key insights and clinical guidelines on deintensified treatment strategies for recurrent low-grade bladder tumors. Here’s the thread 🧵👇

Honored to have contributed to the <a href="/IBCG_BladderCA/">IBCG</a> effort in providing key insights and clinical guidelines on deintensified treatment strategies for recurrent low-grade bladder tumors. Here’s the thread 🧵👇
Roberto Contieri (@robertocontieri) 's Twitter Profile Photo

/6 IBCG Risk-adapted approach for recurrent LG NMIBC: ✅TURBT for tumors >2-3 cm or positive HG UC. ✅AS for low tumor burden, potential transition to TURBT or OF/LA if needed ✅OF/LA for small tumors, flexible on number/size based on patient and urologist preferences

/6 <a href="/IBCG_BladderCA/">IBCG</a> Risk-adapted approach for recurrent LG NMIBC:
✅TURBT for tumors &gt;2-3 cm or positive HG UC.
✅AS for low tumor burden, potential transition to TURBT or OF/LA if needed
✅OF/LA for small tumors, flexible on number/size based on patient and urologist preferences
Roberto Contieri (@robertocontieri) 's Twitter Profile Photo

/7 IBCG highlights the importance of personalized treatment plans based on individual patient factors, tumor behavior, and preferences. Patient education is key for informed decisions! 🌟 Read the full review here: authors.elsevier.com/a/1jheg_wtO--z…

Enrique Grande (@drenriquegrande) 's Twitter Profile Photo

⚡️ Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection #BladderCancer OncoAlert Shilpa Gupta Hikmat Al Ahmadie Ashish M. Kamat, MD, MBBS

⚡️ Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection

#BladderCancer <a href="/OncoAlert/">OncoAlert</a> <a href="/shilpaonc/">Shilpa Gupta</a> <a href="/h_alahmadie/">Hikmat Al Ahmadie</a> <a href="/UroDocAsh/">Ashish M. Kamat, MD, MBBS</a>
Sabine D. Brookman-May (@brookmans76) 's Twitter Profile Photo

Guidance for #BladderSparing treatment IBCG #BladderCancer ✅Several treatment options available to explore bladder sparing approach safely ✅Thorough clinical response assessment needed (consider PDD) ✅ TMT/RC in case of failure Ashish M. Kamat, MD, MBBS OncoDaily Shilpa Gupta

UroToday.com (@urotoday) 's Twitter Profile Photo

Exploring the complexities of #BladderCancer surveillance: cytology, UroVysion, and beyond. Komal Pohar & Kelly Bree discuss urinary markers with Ashish M. Kamat, MD, MBBS as part of this Amer. Urol. Assn. IBCG #BladderCancerForum > bit.ly/4dZmgEv

Exploring the complexities of #BladderCancer surveillance: cytology, UroVysion, and beyond. Komal Pohar &amp; <a href="/KKBree/">Kelly Bree</a> discuss urinary markers with <a href="/UroDocAsh/">Ashish M. Kamat, MD, MBBS</a> as part of this <a href="/AmerUrological/">Amer. Urol. Assn.</a> <a href="/IBCG_BladderCA/">IBCG</a> #BladderCancerForum &gt; bit.ly/4dZmgEv
Stephen B. Williams, MD, MBA, MS, FACHE (@swilliams_md) 's Twitter Profile Photo

Excited to see this work by the exceptional team Valar Labs presented at #IBCN24 IBCN in Bern 🇨🇭 👉large international cohort validating a novel AI powered bladder cancer histologic biomarker predicts outcomes.🔥👍💫 Bladder Cancer Advocacy Network UroToday.com IBCG UTMBUrology

Excited to see this work by the exceptional team <a href="/valarlabs/">Valar Labs</a> presented at #IBCN24 <a href="/IBCN1997/">IBCN</a> in Bern 🇨🇭 👉large international cohort validating a novel AI powered bladder cancer histologic biomarker predicts outcomes.🔥👍💫 <a href="/BladderCancerUS/">Bladder Cancer Advocacy Network</a> <a href="/urotoday/">UroToday.com</a> <a href="/IBCG_BladderCA/">IBCG</a> <a href="/UTMBUrology/">UTMBUrology</a>
Stephen B. Williams, MD, MBA, MS, FACHE (@swilliams_md) 's Twitter Profile Photo

Andrea Necchi presenting #IBCN24 IBCN SunRise 4 Neoadjuvant TAR 200 + cetrelimab v cetrelimab alone MIBC interim analysis showing significantly improve pCR and pOR rates for TAR 200 combo! Marked patients T2 & complete TURBT. IBCG Bladder Cancer Advocacy Network UroToday.com

<a href="/AndreaNecchi/">Andrea Necchi</a> presenting #IBCN24 <a href="/IBCN1997/">IBCN</a> SunRise 4 Neoadjuvant TAR 200 + cetrelimab v cetrelimab alone MIBC interim analysis showing significantly improve pCR and pOR rates for TAR 200 combo! Marked patients T2 &amp; complete TURBT. <a href="/IBCG_BladderCA/">IBCG</a> <a href="/BladderCancerUS/">Bladder Cancer Advocacy Network</a> <a href="/urotoday/">UroToday.com</a>